#1AstraZeneca B What science can do H1 2021 results Conference call and webcast for investors and analysts 29 July 2021 RSTEGA#2Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast. B 2#33 Speakers Pascal Soriot Executive Director and Chief Executive Officer Mene Pangalos Executive Vice President, BioPharmaceuticals R&D Dave Fredrickson Executive Vice President, Oncology Business Unit Susan Galbraith Executive Vice President, Oncology R&D Ruud Dobber Executive Vice President, BioPharmaceuticals Business Unit Leon Wang Executive Vice President, International and China President (for Q&A) Marc Dunoyer Executive Director and Chief Financial Officer Aradhana Sarin Chief Financial Officer elect (for Q&A) 4#44 Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A B#5H1 2021: growth profile enhanced Key highlights Total revenue +18%, incl. 9% from the pandemic COVID-19¹ vaccine. Total revenue excl. vaccine +9% Q2 growth 12% excl. vaccine Growth: Oncology +15% and New CVRM² +16 %. Respiratory & Immunology +6%. Emerging markets +21% Core operating profit +20%, supported by core 001³ (+115%) Core EPS4 $2.53 (+27%), incl. 14% tax rate. Impact of pandemic vaccine $(0.04) Pipeline news accelerated, incl. close-to-market opportunities ESG5: large boost in pandemic vaccine; about one billion doses released for supply as of today across the network of collaborators Alexion acquisition now closed; consolidation well underway 2021 guidance updated: total revenue is expected to increase by a low-twenties percentage, accompanied by a faster growth in core EPS to $5.05 to $5.40 B Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for first-half (H1) 2021, unless stated otherwise. Guidance at CER and excludes the pandemic COVID-19 vaccine. 1. Coronavirus disease; an infectious disease caused by a newly discovered coronavirus 2. New Cardiovascular, Renal & Metabolism comprising Farxiga, Brilinta, Diabetes and Renal 3. Other operating income 4. Earnings per share 5. Environmental, social and (corporate) governance (topics). 5#6Late-stage pipeline fuelling growth Milestones since the Q1'21 results update Regulatory approval or other regulatory action Regulatory submission acceptance and/or submission Major Phase III data readout or other significant development Medicine Tagrisso Imfinzi Lynparza Koselugo Orpathys Farxiga COVID-19 vaccine Symbicort Fasenra tezepelumab Imfinzi + tremelimumab Forxiga roxadustat nirsevimab AZD7442 Indication (geography) adjuvant NSCLC1¹ (EGFRm2): approval (EU) ES-SCLC³: approval (CN) prostate cancer (2nd line4) (BRCAm5): approval (CN) NF16: approval (EU) lung cancer (2nd line) (MET exon 147): approval (CN) CKD8: approval (US) COVID-19: approval (JP) mild asthma: regulatory submission voluntarily withdrawn (EU) nasal polyps: regulatory submission (US) asthma: regulatory submission (US, EU, JP) NSCLC (1st line) (POSEIDON): Phase III OS9 primary endpoint met CKD: positive regulatory opinion (EU) CKD: negative outcome from US FDA advisory committee RSV10: Phase II/III primary safety objective met SARS-CoV-2 (STORM CHASER): Phase III primary endpoint not met 1. Non-small cell lung cancer 2. Epidermal growth factor receptor mutation 3. Extensive-stage small cell lung cancer 4. 2nd treatment in the metastatic setting; 1st line/1L, 2nd line/2L, 3rd line/3L used across this presentation 5. Breast cancer susceptibility gene 1/2 mutation 6. Neurofibromatosis type 1 7. MET exon 14 skipping alterations 8. Chronic kidney disease 9. Overall survival 10. Respiratory syncytial virus. Status as of 29 July 2021. 6 4#7H1 2021: total revenue +18% Vaccine contributed 9% of growth Total revenue growth, per cent Total revenue excl. pandemic COVID-19 vaccine up by 9% in H1 2021 and by 12% in Q2 2021 ™ FY 2015 FY 2016 FY 2017 Q1 2018 Q2 2018 Q3 2018 14% 11% 18% 22% 5% 17% 11% Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 3% Q3 2020 10% Q4 2020 4% 7% Q1 2021 13% 12% Total revenue excluding pandemic COVID-19 vaccine (with negative growth in dark grey) Pandemic COVID-19 vaccine Changes at CER. 7 Q2 2021 Brilinta Bevespi Koselugo Lokelma New medicines the major contributor +$1.7bn incremental revenue of the new medicines compared to H1 2020¹ Enhertu Breztri roxadustat Fasenra Lynparza Imfinzi Tagrisso Calquence Farxiga Oncology New CVRM Respiratory & Immunology Absolute values at CER. 1. Total revenue for Farxiga, Tagrisso, Calquence, Imfinzi, Lynparza, Fasenra, roxadustat, Breztri, Enhertu, Lokelma, Koselugo, Bevespi and Brilinta. $m 550 450 350 250 150 50 -50 -150 3#8H1 2021: growth profile enhanced Oncology and New CVRM drove growth Oncology New CVRM Respiratory & Immunology Other medicines Total revenue excl. vaccine Pandemic COVID-19 vaccine Total revenue Growth across disease areas H1 ‘21 growth $m % 6,360 2,731 2,970 14,371 1,169 2,310 (6) 15,540 15 Total revenue at actual exchange rates; changes at CER. 8 16 6 9 18 ratio % 41 18 19 15 92 100 Q2 '21 growth $m % 3,337 1,425 1,424 1,140 7,326 894 8,220 14 16 21 (8) 12 25 ratio % 41 17 17 14 89 11 100 EM¹ - EM excl. China - China US Europe Established rest of world Total revenue Growth across geographies growth % H1‘21 $m 5,459 2,250 3,209 4,834 3,261 1,986 15,540 21 36 11 16 21 13 18 Total revenue at actual exchange rates; changes at CER. 1. Emerging markets. ratio % 35 14 21 31 21 13 100 Q2 '21 $m 2,868 1,337 1,531 2,524 1,715 1,113 8,220 growth % 32 63 12 21 24 20 25 ratio % 35 16 19 31 21 14 100 B#99 Alexion acquisition closed Integration and synergies next & AstraZeneca Acquisition closed on 21 July 2021 Alexion delisted and the AstraZeneca share base expanded Strong strategic rationale - accelerate expansion into immunology and rare diseases further-sustained, industry-leading ALEXION double-digit revenue growth - - improved profitability and strengthened cash flow AstraZeneca Rare Diseases B#10Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 10 B#11Tagrisso and Imfinzi Growth improved across the lung cancer franchise $m 1,400 1,200 1,000 800 600 400 200 0 Q1 2018 Q2 2018 Q3 2018 Tagrisso: 17% growth to $2.5bn Approvals 57 (adjuvant), 91 (1L), 91 (2L)¹ Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 US Europe Established Rest of World (EROW) EM Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 11 Q4 2020 Q1 2021 Q2 2021 ● ● ● US +18% (35% of total) Diagnoses started to recover offset by a high penetration Europe +30% 1st-line adoption increased further in several countries EROW +13% Japan: +7%; c.78% 1st-line penetration² EM +10% China +4%. 1st-line NRDL³ implementation underway 1. Reimbursement in 11, 46 and 67 countries, respectively. 2. Total prescription share, Diary market research, June 2021. 3. National Reimbursement Drug List. $m 700 600 500 400 300 200 100 T T Q1 2018 Q2 2018 Q3 2018 Q4 Imfinzi: 18% growth to $1.2bn Approvals 734 (NSCLC5), 574 (ES-SCLC6) 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 US Europe EROW EM Total revenue at actual rates; changes exchange at CER and for H1 2021, unless stated otherwise. Q4 2020 Q1 2021 Q2 2021 ● ● ● ● US +4% (51% of total) Diagnoses improved; SCLC use the primary driver Europe +23% Growth driven by SCLC use and more reimbursements EROW +30% Japan: +36%; diagnoses subdued; SCLC growth EM +99% China NSCLC launch continued strongly 4. Reimbursement in 34 and nine countries, respectively. 5. Unresectable, Stage III NSCLC. 6. Extensive-stage small cell lung cancer. g#12Lynparza The globally-leading PARP¹ inhibitor $m 12 700 600 500 400 300 200 100 Q1 2018 Q2 2018 Q3 2018 34% growth in sales to $1.1bn Q4 2018 Q1 2019 CO2 2019 Q3 2019 %Q4 2019 Product sales at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 1. Poly ADP ribose polymerase. Q1 2020 Q2 2020 Lynnarza Q3 2020 Q4 2020 Q1 2021 Q2 2021 As ● Approvals 84 (ovarian), 82 (breast), 63 (pancreatic) and 60 (prostate cancer) AstraZeneca US +29% (46% of total) Growth primarily driven by use in prostate cancer Europe +38% Growth in 1st-line OC² and in prostate cancer EM +50% Expanded China NRDL supported OC EROW +26% Japan: +20%; c.14% Q2 2020 price cut 2. Ovarian cancer. Ĵ Q3 2017 Q4 2017 Q1 2018 Upfront payment Q2 2018 Collaboration revenue Q3 2018 Q4 2018 Option Q1 2019 payments Q2 2019 Q3 2019 Q4 2019 Q1 2020 Regulatory Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 $m Collaboration revenue at actual exchange rates. Collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known as MSD out- side the US and Canada. $3.1bn revenue recorded; $4.6bn future potential. 1,000 800 600 400 200 0 milestones Sales milestones B THE TRE FOR P#13Calquence and Enhertu Launches continued ahead Calquence: 150% growth to $0.5bn $m Approvals: 66 (CLL¹) and 32 countries (MCL²)³ 350 300 250 200 150 100 50 0 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 ● ● ● Global $490m; US $445m US CLL Earlier use; share of new patients: Front line c.45% of BTKI4 class and >15% overall5 Relapsed/refractory c.45% of BTKi class; c.20% overall5 Global CLL DE, UK largest contributors US Europe EROW EM Total revenue at actual exchange rates. 1. Chronic lymphocytic leukaemia 2. Mantle cell lymphoma (R/R) 3. Reimbursement in 15 and 10 countries, respectively 4. Bruton tyrosine kinase inhibitor 5. IQVIA market research. 13 $m 50 25 Q1 2020 Enhertu Approvals: US, EU, JP (mBCº); US, JP (mGC7) Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 ● Global $89m; US $75m $161m total US in-market sales by Daiichi Sankyo France early access and early launch sales elsewhere, incl. UK 00-406-41 ENHERTU -rastrual dedica nection B 100 mg per vial nu insion Onl and Dute pro to Cytotec Age NDC 65597-406-01 Rx only ENHERTUⓇ (fam-trastuzumab deruxtecan-nxki) For Injection 100 mg per vial For Intravenous Infusion Only Dispense the enclosed Medication Guide to each patient. Reconstitute and Dilute prior to administration Single-Dose Vial Discard Unused Portion CAUTION: Cytotoxic Agent KEEP REFRIGERATED 1 vial Daiichi-Sankyo AstraZeneca US Europe EM Total revenue at actual exchange rates, including $4m of sales. 6. Metastatic breast cancer (3L, HER2+) 7. Metastatic gastric cancer (3L/2L+, HER2+). 3#14BioPharmaceuticals: commercial and pre-launch headlines Key priorities from March 2021 capital markets event being delivered 38% CVRM Delivery of Farxiga lifecycle opportunities 46% Global 26% US 38% 31% 24% 1 Europe 63% Market growth Farxiga growth 1. Sodium-glucose co-transporter 2 inhibitor. Source: IQVIA market research, volume growth/treatment days, YTD May 2021. 14 EM 60% Farxiga outperformed SGLT2i¹ class volume growth 21% 34% Japan Respiratory & Immunology Positive pre-launch milestones 20 Fasenra asthma - MELTEMI Phase III trial presented enraa nasal polyps - regulatory submission acceptance (US) tezepelumab asthma - regulatory: priority review (US), submission (EU, JP) and NAVIGATOR/SOURCE Phase III trial publication/presentation Synagis Reverted to AstraZeneca ownership outside the US nirsevimab RSV - second positive registrational trial, MEDLEY Phase II/III trial anifrolumab lupus (SLE²) - TULIP-1/2 Phase III trial new data presentation 2. Systemic lupus erythematosus. Broad progress across key new opportunities#15BioPharmaceuticals: New CVRM 16% growth driven by Farxiga and Renal $m 1,500 1,250 1,000 750 500 250 Q1 2018 Q2 2018 Q3 2018 Q4 2018 New CVRM 16% growth Q1 2019 Q2 2019 Q3 2019 Farxiga Brilinta Diabetes Renal Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 15 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 $m 750 500 250 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Farxiga 53% growth - the fastest-growing SGLT2i globally Q2 2019 Q3 2019 Q4 2019 US Europe EROW EM Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 US +27% Strong market share growth boosted by HFrEF¹ indication and CKD launch Europe +51% Strong volume growth boosted by launch of HFrEF indication EM +77% Benefit from NRDL inclusion in China and strong growth outside China 4 1. Heart failure with reduced ejection fraction.#16BioPharmaceuticals: Respiratory & Immunology 6% growth with improved year-on-year performance in Q2 $m 1,750 1,500 1,250 1,000 750 500 250 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Respiratory 6% growth Q1 2019 Q2 2019 Q3 2019 Fasenra Symbicort Pulmicort Other Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 16 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Improved performance with new medicines offsetting mature ones US +17% Symbicort (-5%); H1 2020 inventory and COVID-19 effect. Fasenra (+31%) Europe -5% Symbicort (-12%); partial offset by Fasenra (+39%) EROW -14% Japan: -17%; increasing Symbicort generic competition. Fasenra (+14%) EM +10% Pulmicort ($405m, +2%) ; increased respiratory infections offset by generic competition. VBP¹ impact in H2 2021 Maintenance use with Symbicort ($306m, +2%) 11-2018 PBHE PULMICORT 1 mg/2m W Pulmicort 1mg in 2 mL restules Sterle single-dose un user uspersion 1. Volume-based procurement. 5 x 2mL อาชนทราย ยาเฉพาะ AstraZeneca. Fasenra Pen 30 mg/mL (benvallzumab Pjection p Symbicort 3#17BioPharmaceuticals: new launch medicines Portfolio of new medicines across uses and markets Leading new biologic in five of top-seven countries ¹ US, total patient share Europe $136m (+39%); Japan $54m (+14%) 100% US $357m (+31%) 80% 60% 40% Severe asthma 20% Fasenra 0% T Q4 2017 Q2 2018 Q4 2018 Q2 2019 Q4 2019 Q2 2020 pe24 2020 52% 48% Q2 2021 Total revenue at actual exchange rates. 1. Market shares are new patient share in severe, uncontrolled asthma; US: specialty pharmacies and 'buy and bill' market, IQVIA market research. 17 Breztri COPD² US $43m Achieved >20% share of new patients³ EM $27m Continued launch in China; NRDL inclusion in place Japan $11m Achieved >35% share of new patients³ ストリエアロスフィア ピレーズトリ エアロスフィア 56双入 FASUDAAN GHASKA TS 2. Chronic obstructive pulmonary disease 3. New patient share in triple COPD market, IQVIA market research. $m 60 50 40 30 20 10 0 Lokelma Hyperkalaemia Global $72m; US $49m US market leadership4, new and total prescriptions Global launch continued Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 T₁ Q2 2021 US Europe EROW EM Total revenue at actual exchange rates. 4. Market leadership in both total and new-to-medicine patients, IQVIA market research. $m 60 50 40 30 20 10 0 EM $92m Recording sales in China since Q1 2021 US roxadustat Anaemia in CKD Disappointing advisory committee 15 July 2021; regulatory decision H2'21 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 EM Total revenue at actual exchange rates. Q2 2021 3#18Emerging markets Diverse and solid growth $m 3,000 2,500 2,000 1,500 1,000 500 Q1 2018 Q2 2018 Q3 2018 Emerging markets +21% EM excl. China +36%; China +11% Q4 2018 Q1 2019 Q2 2019 Q3 2019 China EM excluding China Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 18 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Performance driven by new medicines up 29% (35% of total revenue; $1.8bn¹) Oncology +6%: Tagrisso (+10%) ; March 2021 NRDL inclusion New CVRM +28%: Forxiga (+77%) ; roxadustat ($92m) Respiratory & Immunology +10%: Pulmicort ($405m, +2%); Symbicort ($306m, +2%) Diversified growth: AP² +4%, MEA³ +73%, LA4¹ +48%, Russia +6%; benefit from vaccine shipments 2021 China patient access: major NRDL inclusion Tagrisso 1L but VBP impact to now Pulmicort, Brilinta, Nexium and legacy Revenue anticipated to continue growing ahead of the long-term ambition of mid to high single-digit growth Total revenue at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 1. Total revenue at CER 2. Asia Pacific 3. Middle East, Africa and other 4. Latin America. 3#19Rare diseases: a new disease area in AstraZeneca Consolidation and financial reporting to start from closing Total revenue Soliris Ultomiris Strensiq Kanuma Alexion pre-acquisition stand- alone H1 and Q2 2021 revenue Andexxa H1 2021 $3,337m | +15% $2,099m | +5% $701m | +48% $405m | +14% $67m | +12% $64m | n/m Absolute values at actual exchange rates; changes at CER. Originally reported by Alexion on 20 July 2021 and not adjusted for consistency with AstraZeneca's accounting policies, not audited and not included in AstraZeneca's H1 2021 results. 19 Q2 2021 $1,700m | +18% $1,071m | +10% $354m | +41% $208m | +13% $33m | -3% $35m n/m Future financial reporting Alexion consolidated upon deal closing on 21 July 2021 New strategic disease area Oncology Rare diseases Cardiovascular, Renal & Metabolism Respiratory & Immunology To be included in YTD and Q3 2021 results on 12 November 4#20Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 20 B#21Reported profit and loss Total revenue - product sales - collaboration revenue Gross margin Operating expenses¹ - R&D² expenses - SG&A³ expenses Other operating income Operating profit Tax rate EPS H1 2021 $m 15,540 15,302 238 73.5% 9,771 3,542 6,027 1,308 3,022 11.0% $1.61 change % 18 19 (12) (6.1) pp4 12 22 7 116 25 45 % total revenue 100 98 2 63 23 39 8 19 Q2 2021 $m 8,220 8,045 175 72.8% 5,030 1,829 3,098 128 1,127 28.0% $0.42 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales. 1. Includes distribution expenses 2. Research and development 3. Sales, general and administration 4. Percentage points. 21 change % 25 27 (23) (9.6) pp 15 25 11 1 (4) (15) % total revenue 100 98 2 61 22 38 2 14 3#22Core profit and loss Total revenue - product sales - collaboration revenue Gross margin Operating expenses - R&D expenses - SG&A expenses Other operating income Operating profit Tax rate EPS H1 2021 $m 15,540 15,302 238 73.8% 8,511 3,439 4,870 1,309 4,329 14.3% $2.53 $(0.04) change % 18 19 (12) (6.4) pp 12 21 7 115 20 27 % total revenue 100 98 2 55 22 31 8 28 Q2 2021 $m 8,220 8,045 175 73.0% 4,375 1,801 2,471 129 1,805 23.6% $0.90 $(0.01) Impact of pandemic vaccine on EPS Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales. 22 change % 25 27 (23) (9.9) pp 13 24 7 (2) 5 (2) % total revenue 100 98 2 53 22 30 2 22 B#23Analysis: core operating profit and net debt Continued improvement in the operating profit mix $m 2,750 23 2,500 2,250 2,000 1,750 1,500 1,250 1,000 750 500 250 0 Q3 2017 Q4 2017 Core operating profit mix improved Residual from product sales increased Q1 2018 Q2 2018 Absolute values at actual exchange rates. Return Return to to sales revenue growth growth Residual Collaboration revenue (CR) Core OOI Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 $bn 12.1 Net debt end 2020 Net debt reduced from improved EBITDA¹, working capital reductions 4.6 EBITDA 0.9 Working capital, short-term provisions 1.3 Other operating cash, disposals 0.5 Capex 0.6 and non-current asset investments Contingent and intangible assets Net debt: $11,721m EBITDA: $8,828m 2.5 Dividends 0.2 Other 11.7 Net debt end June 2021 1. Earnings before interest, tax, depreciation and amortisation; last four quarters ($8,828m vs. $7,748m one year ago) Moody's: short-term rating P-2, long-term rating A3, outlook negative. AstraZeneca credit ratings: Standard & Poor's: short-term rating A-2, long-term rating A-, CreditWatch neutral. 3#24Financial priorities H1 2021 results underpinned the strategic journey Deleveraging/dividend growth As cash flow improves, deleveraging and progressive dividend policy 24 ● Unchanged priorities for capital allocation. Cash-flow growth 14% growth in reported EBITDA and continued improvement in working capital management ● 2021: anticipate further improvement in cash flow, cash- flow metrics and dividend cover Changes at CER. ● ● Revenue growth +9% growth in total revenue in H1 2021 excl. the pan- demic COVID-19 vaccine Operating leverage 55% ratio of core operating expenses to total revenue (down 3.0 pp) 20% growth in core operating profit ● • 28% core operating profit margin incl. contribution from OOI B#252021 guidance updated Alexion is now included Total revenue increase by a low- twenties percentage Core EPS faster growth to $5.05 to $5.40 Based on 1,418 million weighted average number of shares in issue during 2021 The guidance does not incorporate any revenue or profit impact from sales of the pandemic COVID-19 vaccine. In general, AstraZeneca continues to recognise the heightened risks and uncertainties from the effects of COVID-19, including the impact from potential new medicines for COVID-19 in clinical development. Variations in performance between quarters can be expected to continue. 25 B#26Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 26 B#27Continuing response to COVID-19 Vaxzevria and AZD2816 Vaxzevria (pandemic COVID-19 vaccine) 92% effectiveness against hospitalisation and death from the delta variant¹ 82% effectiveness against hospitalisation and death from beta or gamma variant² 1 year+ of demonstrated immunity after a single dose and strong response to a late second dose³ 1. Effectiveness of COVID-19 vaccines against hospital admission with the delta variant (B.1.617.2), PHE, 14 June 2021 2. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada, Kwong et al, 16 July 2021 3. Parry HM, et al., preprint with The Lancet. 27 Global equitable supply >700m doses released for global supply by the extended supply chain incl. Serum Institute of India as of June 2021 c.319m doses invoiced in H1 2021 by AstraZeneca incl. c.97m to the EU c.90% of COVAX4 supply to more than 125 countries 4. Vaccines pillar of the ACT Accelerator, a partnership launched by the World Health Organization. AZD2816 (new variant vaccine) Phase II/III trial launched Vaccinated and vaccine-naive population Based on genetic modifications of the beta variant, the most highly- mutated variant of concern Read-out anticipated in H2 2021 Building on early success in the fight against pandemic 3#28CVRM: Farxiga a new standard of care From a start in diabetes now to HF and CKD HFrEF: 26% risk reduction in primary endpoint Cumulative Percentage (%) DAPA-HF Phase III trial 3- HR¹0.74 (0.65,0.85) p=0.00001 NNT=21 Number at Risk Dapagliflozin 2373 2305 2371 Placebo 2258 2221 2163 9 15 Months since Randomization 2147 2075 12 2002 1917 1560 1478 18 1146 1096 HF use now approved in all major markets Dapagliflozin 21 612 593 Placebo 1. Hazard ratio. Source: Hot Line Session 1, European Society of Cardiology (ESC) 2019. 28 24 210 210 [. First SGLT2i with benefit in patients with and without T2D² Cumulative Incidence (%) No. at Risk Dapagliflozin Placebo 24 22 20 18 16- 14 12 10 8 6 4 2 0 0 DAPA-CKD Phase III trial Hazard ratio, 0.61 (95% CI, 0.51-0.72) p=0.000000028 NNT=19 2152 2152 2001 1993 8 1955 1936 1898 1858 12 Months since Randomization 16 2. Type-2 diabetes. Source: Hot Line Session, ESC 2020. 20 1841 1791 1701 1664 Placebo Dapagliflozin 24 1288 1232 28 831 774 312 Events Secondary endpoints met, incl. all-cause mortality 197 Events 32 309 270 Milestones and news flow CKD: approval (US); positive opinion (EU) First patient dosed in Phase II trials of Farxiga + AZD9977 (HF w/CKD) and Farxiga + zibotentan (CKD) DELIVER Phase III trial in HFpEF³ with data in H1 2022 MYA 1077 farxiga dapagliflozin tablets 5 mg www HW- farxiga dapaglificen tablets 10 mg 3. Heart failure with preserved ejection fraction. 24 3#29Respiratory & Immunology: anifrolumab Potential first-in-class biologic medicine in lupus Compelling data in resolution of skin rash and arthritis Post-hoc analysis of TULIP clinical-trial programme presented at EULAR 2021 A SLEDAI-2K-defined resolution of rash Responders (%) 100 90 80 70 60 50 40 30 20 10 0 P<0.001 anifrolumab placebo 38.4 24.9 n= 123 79 'n= 321 318 All patients P<0.001 41.2 24.2 P=0.746 25.4 28.2 109 63 14 16 266 261 57 55 IFNCS test-high IFNCS test-low Improved the two most impacted organs in SLE Source: abstract 0131, European League Against Rheumatism (EULAR) 2021. 29 Large unmet medical need c.5m lupus patients globally¹ Only 14% treated with a biologic medicine² 80% moderate to severe SLE patients are on OCS3,2 80% of SLE patients have skin manifestations4 Potentially the first new SLE treatment in more than a decade 1. The Lupus Foundation of America 2. AstraZeneca data on file 3. Oral corticosteroids. 4. Kole AK, Ghosh A. Indian J Dermatol. 2009;54(2):132-136, The Lupus Foundation of America. Milestones and news flow US5, EU, JP regulatory decisions in H2 2021 Phase III trial underway for subcutaneous delivery Phase III trials planned in cutaneous lupus erythematosus, lupus nephritis and myositis Potential patient benefit in interferon-driven diseases 5. US Prescription Drug User Fee Act (PDUFA) date in Q3 2021. B#30BioPharmaceuticals: 'What's next' Expanding pipeline, including immunology What's next Phase I/II new medicines, selected MEDI3506 (IL33¹ mAb²) DKD³ 30 cotadutide (GLP-14/glucagon co-agonist) NASH5, DKD AZD4831 (MPO6 inhibitor) HFpEF AZD5718 (FLAP7 inhibitor) CKD, CAD8 AZD9977 + Farxiga (MCR modulator + SGLT2i) HF with CKD Phase II started ✓ zibotentan + Farxiga Phase II (ETR¹0 antagonist +SGLT2i) started ✓ CKD MEDI3506 (IL33 mAb) COPD, asthma AD¹¹, COVID-19 AZD1402 (IL4Ra ¹2 antagonist) asthma AZD0449, AZD4604 (inhaled JAK¹3 inhibitors) asthma MEDI7352 (NGF¹4 TNF¹5 bispecific fusion protein) - pain AZD2693 (PNPLA3¹6 inhibitor) NASH AZD8233 (PCSK9¹7 ASO¹8) hypercholesterolaemia Phase II started ✓ What's now Phase III new medicines roxadustat anaemia in CKD nirsevimab RSV Positive Ph II/III ✓ brazikumab inflammatory bowel disease19 PT027 asthma Combos Farxiga in Ph II multiple indications Reg. tezepelumab subm. multiple indications anifrolumab lupus (SLE) Phase III lifecycle management, major Fasenra PDUFA Q3 2021 multiple indications Breztri asthma 1. Interleukin-33 2. Monoclonal antibody 3. Diabetic kidney disease 4. Glucagon-like peptide 1 5. Non-alcoholic steatohepatitis 6. Myeloperoxidase 7.5-lipoxygenase-activating protein 8. Coronary artery disease 9. Mineralocorticoid receptor 10. Endothelin re- ceptor 11. Atopic dermatitis (eczema) 12. Interleukin-4 receptor alpha 13. Janus kinase 14. Nerve growth factor 15. Tumour necrosis factor 16. Patatin-like phospholipase domain-containing protein 3 17. Proprotein convertase subtilisin/kexin type 9 18. Antisense oligonucleotide 19. Trial technically classified as Phase II.#31Oncology: 2021 ASCO Annual Meeting Further solid progress in redefining cancer care 2021 ASCO Annual Meeting: another strong presence - 90 abstracts and 74 presentations¹ One plenary session (Lynparza OlympiA Phase III trial; adjuvant breast cancer); 12 oral presentations; 14 poster discussions; 47 posters; and 16 abstracts (publication only) Calquence ELEVATE-TN Phase III four-year follow-up ELEVATE-RR Phase III vs. ibrutinib Imfinzi PACIFIC Phase III five-year overall survival Enhertu, datopotamab deruxtecan, other potential new medicines from the pipeline 1. 24 additional presentations at ASCO 2021 featured AstraZeneca medicines and potential new medicines but were not supported by AstraZeneca. Source: ASCO 2021 accepted abstracts. 31 Lynparza demonstrated a sustainable and clinically meaningful treatment effect compared to placebo² Invasive disease-free survival (%) No. at risk 100 80 60 40 20 Olaparib Placebo 0 0 921 915 93.3 Olaparib (106 events) Placebo (178 events) T 6 88.4 Stratified hazard ratio 0.58 (99.5% CI, 0.41-0.82); P<0.0001 Difference: 3-year IDFS rate 8.8% (95% CI, 4.5-13.0%) T T 24 18 820 807 89.2 737 732 81.5 T 12 Time since randomization (months) 607 585 477 452 T 30 361 353 85.9 77.1 36 276 256 42 183 173 2. With germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Source: ASCO 2021 accepted abstracts. Abstract LBA01, plenary session, ASCO 2021. 3#32Koselugo and Orpathys 'Rare' opportunities to make a significant difference in the lives of patients Koselugo approved in the EU for children with neuro- fibromatosis type 1 and plexiform neurofibromas (PN) 66% Patients met the primary endpoint of ≥20% reduction in target NF1 PN volume¹ 82% Patients with partial responses remained in response after 12 months² 27% Median best percentage change in target NF1 PN volume from baseline Radiographic example of a response Pre-treatment Post-treatment 1. Compared to baseline (95% confidence interval [CI]: 51%-79%). The ORR assessment was conducted by a single National Cancer Institute reviewer who was a SPRINT trial investigator and who evaluated all PN imaging from patients enrolled at all trial sites Koselugo prescribing information. Images courtesy of Dr. Miriam Bornhorst. 32 Orpathys approved in China for NSCLC with MET gene alterations 17.6 months Median follow up 42.9% Overall response rate³ 6.8 months Progression-free survival4 in the overall trial population Monotherapy approval for Orpathys Phase III combo programme ongoing 3 3. 95% CI 31.1-55.3. 4. 95% CI 4.2-9.6. Source: The Lancet Respiratory Medicine, June 2021.#33Oncology: 'What's next' Solid pipeline moving forward What's next Phase I/II new medicines, selected adavosertib (WEE1¹ inhibitor) uterine, ovarian cancer oleclumab (CD73² mAb) solid tumours AZD5305 (PARP1 inhibitor) solid tumours AZD4573 (CDK9³ inhibitor) blood cancers AZD5991 (MCL14 inhibitor) blood cancers Phase I w/CTx ✓ ceralasertib (ATR5 inhibitor) solid tumours, blood cancers imaradenant (formerly AZD4635) (A2AR6 inhibitor) solid tumours MEDI5752 (PD-17/CTLA48 mAb) solid tumours AZD2811 (Aurora B inhibitor) solid tumours AZD0466 (Bcl-29/XL) blood cancers New Phase II New Phase I ✓ 1. Tyrosine kinase WEE1 2.5'-nucleotidase 3. Cyclin-dependent kinase 9 4. Induced myeloid leukaemia cell differentiation protein 5. Ataxia telangiectasia and rad3-related kinase 6. Adenosine A2A receptor 7. Programmed cell death protein 1 8. Cytotoxic T-lymphocyte-associated protein 4 9. B-cell lymphoma 2 10. Potentially pivotal Phase II. 33 What's now datopotamab deruxtecan lung cancer monalizumab head & neck cancer Orpathys NSCLC10 First approval Tagrisso NSCLC Phase III new medicines Imfinzi multiple cancers camizestrant breast cancer capivasertib breast, prostate cancer tremelimumab multiple cancers Phase III lifecycle management, major Lynparza multiple cancers New Phase III ✓ New Phase III Enhertu multiple cancers Calquence multiple cancers#34Late-stage pipeline events over the next 18 months News flow picks up; Phase III readouts increase into H2'21 Regulatory decision Regulatory submission acceptance and/or submission Key Phase III data readout H2 2021 Forxiga - CKD (EU, JP) roxadustat - anaemia in CKD (US) anifrolumab - lupus (SLE) (US, EU, JP) Imfinzi + tremelimumab - NSCLC (1L) (POSEIDON) Lynparza - adjuvant breast cancer Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (2L, HER2+) Calquence - CLL (R/R) (ELEVATE-RR) COVID-19 vaccine - COVID-19 (US) AZD7442 - SARS-CoV-2 Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi +/-treme - liver cancer (1L) Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (2L, HER2+)¹ PT027-asthma AZD7442 - SARS-CoV-2 Status as of 29 July 2021. 1. Based on a planned interim analysis as communicated by Daiichi Sankyo in Q2 of their fiscal year 2021. 34 H1 2022 Brilique - stroke (THALES) (EU, CN) Forxiga - CKD (CN) Fasenra - nasal polyps (US) tezepelumab - asthma (US, EU, JP) Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi +/-treme - liver cancer (1L) Enhertu - breast cancer (HER2 low) Calquence - CLL (CN) Koselugo - NF1 (JP, CN) Farxiga - HF (HFpEF) PT027 - asthma (US) nirsevimab - RSV Imfinzi - NSCLC (1L) (PEARL) Imfinzi - cervical cancer Enhertu - breast cancer (HER2 low) Farxiga - HF (HFpEF) roxadustat - anaemia in myelodysplastic syndrome H2 2022 Imfinzi - NSCLC (1L) (PEARL) Imfinzi - cervical cancer Imfinzi - biliary tract cancer Enhertu - breast cancer (3L, HER2+) (Phase III) roxadustat - anaemia in myelodysplastic syndrome Fasenra- eosinophilic oesophagitis Imfinzi - limited-stage SCLC Imfinzi - liver cancer (locoregional) (EMERALD-1) Imfinzi - biliary tract cancer Enhertu - breast cancer (3L, HER2+) (Phase III) Fasenra - hyper-eosinophilic syndrome Fasenra- eosinophilic oesophagitis B#35Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 35 B#36AstraZeneca in summary Pipeline-driven transformation Global presence Balanced specialty and primary-care franchises¹ Leading emerging markets presence with R&D base Strong pipeline 22 Phase III medicines and significant lifecycle projects² Advancing early- and mid-stage pipeline Improving financials Ten blockbuster medicines2,3 Returned to durable revenue and earnings growth Focus on operating leverage and cash flow Innovative medicines in Oncology, Rare Diseases & BioPharmaceuticals4 Experienced and proven team 1. In H1 2021, medicines for use in speciality care, typically in the hospital setting (Oncology, Brilinta, Lokelma, roxadustat and Fasenra) comprised 51% of total revenue 2. Alexion to be included from next quarter 3. Last four quarters, excludes COVID-19 vaccine 4. Cardiovascular, Renal & Metabolism and Respiratory & Immunology. 4 36#3725 Questions & Answers 37 4#38Appendix: 'What's next' Next key milestone by project Oncology Project adavosertib ceralasertib oleclumab imaradenant (formerly AZD4635) AZD5305 MEDI5752 AZD4573 AZD2811 AZD5991 AZD0466 Status as of 29 July 2021. 38 Target WEE1 ATR CD73 A2AR PARP1 PD-1/ CTLA4 CDK9 Aurora B MCL1 Bcl-2/xL Phase || || || || I | 1/11 | I 1/11 Indication uterine, ovarian cancer solid tumours blood cancers solid tumours solid tumours solid tumours solid tumours blood cancers solid tumours blood cancers blood cancers Next milestone Phase III start Phase II data Phase II data H2 2021 Phase II data Phase I data Phase II start 2021 Phase I data H2 2021 Phase II data Phase II start 2021 Phase II data BioPharmaceuticals: CVRM Target GLP-1/ glucagon Project cotadutide AZD4831 AZD5718 AZD9977 + Farxiga zibotentan + Farxiga AZD2693 AZD8233 MEDI3506 AZD1402 AZD0449 AZD4604 MPO MEDI7352 FLAP MCR + SGLT2 ETR + SGLT2 PNPLA3 PCSK9 IL33 IL4Ra JAK Phase NGF TNF || || || || || I || BioPharmaceuticals: Respiratory & Immunology | || || I Indication || NASH DKD HFpEF CKD CAD HF with CKD CKD NASH hypercholesterolaemia COPD asthma, AD, COVID-19, DKD asthma asthma pain Next milestone Phase II data H2 2021 Phase II data H2 2022 Phase II start H2 2021 Phase II data H2 2022 Phase II data H2 2022 Phase II data H2 2022 Phase I data H1 2022 Phase II data H2 2021 Phase I data H2 2021 Phase II data H2 2021/ 2022/2022+ Phase II data H2 2022 Phase II start H2 2021 Phase I start H2 2021 Phase II data H2 2022 3#39Appendix: Rare Diseases - a new growth area for AstraZeneca Recent and upcoming pipeline developments 39 Ultomiris gMG¹ (2nd-generation, long-acting C5 inhibitor) • Positive Phase III read-out July 2021; full data to be presented at future medical conference 1. Generalised myasthenia gravis. Regulatory submission to follow in H2 2021 and H1 2022 dadda Idda ddd dddd ddddd વવવા da Q2W IV Addressable gMG market SOLIRIS' (eculizumab) 100/20 Q8W IV ULTOMIRIS [ravulizumab cwvz] w Compelling product profile and value proposition will help expand addressable gMG population dd da lada Future Assets ALXN1840 Wilson Disease Phase III read-out anticipated H2 2021 Novel potential new treatment with convenient once-daily oral dosing Powered for superiority over standard-of-care chelators Potential for rapid and sustained control of copper and clinical symptoms Opportunity to revolutionise treatment in Wilson Disease B#40Appendix: Rare Diseases - 'What's next' Pipeline progress continued What's next Phase I/II new medicines, selected ALXN1720 (3rd-generation C5 inhibitor) gMG ALXN2040 (Factor D inhibitor) Geographic Atrophy ALXN1820 (Anti-properdin) ALXN1830 (anti-FcRn) gMG, WAIHA¹ ALXN2050 (Factor D inhibitor) PNH2, gMG, renal indications ALXN1850 (Next-generation asfotase alfa) Hypophosphatasia 1. Warm autoimmune haemolytic anaemia 2. Paroxysmal nocturnal haemoglobinuria 3. Transthyretin amyloidosis, Japan-only opportunity 4. Extra-vascular haemolysis 5. Guillain-Barré syndrome 6. Neuromyelitis optica spectrum disorder 7. Dermatomyositis, Phase II/III adaptive trial 8. Amyotrophic lateral sclerosis 9. Haematopoietic stem cell transplant thrombotic microangiopathy 10. Complement-mediated thrombotic microangiopathy 11. Phase II basket trial. 40 What's now ALXN1840 Wilson disease AG10 ATTR³ Phase III new medicines Soliris GBS6 (Japan only) CAEL-101 AL-amyloidosis ALXN2040 PNH w/EVH4 Phase III lifecycle management, major Positive gMG gMG, NMOSD6 Ph III Ultomiris DM7, ALS8 HSCT-TMA⁹ CM-TMA¹0, renal indications1¹¹#41Investor Relations Team Cambridge, UK and Boston, US II Photographed responsibly at Stow Cum Quy, Cambridgeshire, UK on 8 July 2021. From left: Phil, Nick, Claire (maternity cover for Rosie), Lauren, Thomas, Christer, Josie, Jen and Tom. 41 Thomas Kudsk Larsen Nick Stone Kevin O'Neil Christer Gruvris Josie Afolabi Tom Waldron Lauren Swales Phil Sparks Jen Kretzmann Claire Denny AZN IR Team members Oncology Rare Diseases BioPharmaceuticals (Cardiovascular, Renal & Metabolism), Finance BioPharmaceuticals (Respiratory & Immunology) Other medicines, COVID-19 Corporate access, investors Corporate access retail +44 203 749 5712 +44 203 749 5716 +1 857 338 8505 +44 203 749 5711 +44 203 749 5631 +44 7385 033 717 +44 7789 595 458 +44 7826 549 396 +44 203 749 5824 +44 7827 882 809 4#4242 Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca materials in any way. You may not edit, alter, adapt or add to the AstraZeneca materials in any way, nor combine the AstraZeneca materials with any other material. You may not download or use the AstraZeneca materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca materials. You may not use the AstraZeneca materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 OAA. Telephone +44 20 3749 5000, www.astrazeneca.com B